Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 24, 2025
|% Change Since: -15.31%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance for BioCryst, with significant growth in Orladeo revenue, positive financial results, and advancements in the clinical pipeline. However, there are challenges with the reauthorization process and foreign exchange impacts, but they are outweighed by the company's achievements and growth projections.Company Guidance
During BioCryst's fourth quarter 2024 earnings call, the company reported a remarkable year with Orladeo's revenue growing by 34% year-over-year, reaching $437.7 million, and total revenue of $450.7 million. The non-GAAP operating profit exceeded expectations, reaching over $60 million, three times the initial plan. The company increased its Orladeo revenue guidance for 2025 to $535-$550 million, driven by strong demand and the positive impact of the Inflation Reduction Act on Medicare patients' affordability. BioCryst also highlighted progress in its pipeline, with clinical advancements in BCX1775 for Netherton syndrome and Avoralstat for diabetic macular edema. The company is on track to submit a new drug application for Orladeo's pediatric use and anticipates positive cash flow and earnings per share in the second half of 2025.Record Orladeo Revenue Growth
Orladeo revenue grew by 34% year-over-year. The company added as many patients in 2024 as in the first year of launch, reflecting excellent execution by the commercial team.
Strong Financial Performance
BioCryst generated a non-GAAP operating profit of over $60 million, which is three times larger than planned. Total revenue for 2024 was $450.7 million.
Pipeline Advancements
Progress in clinical trials for BCX1775 in Netherton syndrome and Avoralstat for diabetic macular edema (DME). Plans to file NDA for Orladeo in pediatric use this year.
Positive Impact of Inflation Reduction Act
Higher percentage of Medicare patients on Orladeo can afford co-payments, increasing revenue guidance for Orladeo to $535 million to $550 million for 2025.
Strong Retention and Prescriber Momentum
97% of HAE treaters are considering prescribing Orladeo, with 59% extremely likely to prescribe to more patients. Positive real-world evidence supporting Orladeo's efficacy.
---
BCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 24, 2025 | $9.21 | $8.29 | -9.99% |
| Nov 04, 2024 | $8.43 | $7.35 | -12.81% |
| Aug 05, 2024 | $7.02 | $7.51 | +6.98% |
| May 06, 2024 | $4.45 | $5.27 | +18.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biocryst Pharmaceuticals (BCRX) report earnings?
Biocryst Pharmaceuticals (BCRX) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Biocryst Pharmaceuticals (BCRX) earnings time?
Biocryst Pharmaceuticals (BCRX) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCRX EPS forecast?
BCRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.07.
---
